{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:30:59Z","timestamp":1789601459720,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Eosinophils have widespread procoagulant effects. Eosinophilic cardiovascular toxicity mostly consists of endomyocardial damage or eosinophilic vasculitis, while reported cases of venous thrombosis (VT) are scarce. We aimed to report on the clinical features and treatment outcomes of patients with unexplained VT and eosinophilia, and to identify predictors of relapse. This retrospective, multicenter, observational study included patients aged over 15\u00a0years with VT, concomitant blood eosinophilia\u2009\u2265\u20091G\/L and without any other moderate-to-strong contributing factors for VT. Fifty-four patients were included. VT was the initial manifestation of eosinophil-related disease in 29 (54%) patients and included pulmonary embolism (52%), deep venous thrombosis (37%), hepatic (11%) and portal vein (9%) thromboses. The median [IQR] absolute eosinophil count at VT onset was 3.3G\/L [1.6\u20137.4]. Underlying eosinophil-related diseases included FIP1L1-PDGFRA-associated chronic myeloid neoplasm (n\u2009=\u20094), Eosinophilic Granulomatosis with Polyangiitis (n\u2009=\u20099), lymphocytic (n\u2009=\u20091) and idiopathic (n\u2009=\u200929) variants of hypereosinophilic syndrome. After a median [IQR] follow-up of 24 [10\u201362] months, 7 (13%) patients had a recurrence of VT. In multivariate analysis, persistent eosinophilia was the sole variable associated with a shorter time to VT relapse (HR 7.48; CI95% [1.94\u201329.47]; p\u2009=\u20090.015). Long-term normalization of eosinophil count could prevent the recurrence of VT in a subset of patients with unexplained VT and eosinophilia\u2009\u2265\u20091G\/L.<\/jats:p>","DOI":"10.1038\/s41598-021-85852-9","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T16:47:41Z","timestamp":1616086061000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Venous thrombosis and predictors of relapse in eosinophil-related diseases"],"prefix":"10.1038","volume":"11","author":[{"given":"Val\u00e9riane","family":"R\u00e9au","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Vall\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Terrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Plessier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Abisror","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e9lix","family":"Ackermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Benainous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9r\u00f4me","family":"Bohelay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Chabi-Charvillat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divi","family":"Cornec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Claire","family":"Desbois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Faguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Freymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Gaillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Hamidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Killian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Le Jeune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Osorio-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kewin","family":"Panel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Emmanuel","family":"Rautou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Rohmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colas","family":"Tcherakian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Vasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elina","family":"Zuelgaray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Lefevre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Emmanuel","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Groh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,18]]},"reference":[{"key":"85852_CR1","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","volume":"130","author":"P Valent","year":"2012","unstructured":"Valent, P. et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J. Allergy Clin. Immunol. 130, 607\u2013612 (2012).","journal-title":"J. Allergy Clin. Immunol."},{"key":"85852_CR2","first-page":"767","volume":"69","author":"M Groh","year":"2019","unstructured":"Groh, M., Lef\u00e8vre, G., Ackermann, F., \u00c9tienne, N. & Kahn, J.-E. Hypereosinophilic syndromes. Rev. Prat. 69, 767\u2013773 (2019).","journal-title":"Rev. Prat."},{"key":"85852_CR3","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.iac.2007.07.001","volume":"27","author":"P Ogbogu","year":"2007","unstructured":"Ogbogu, P., Rosing, D. R. & Horne, M. K. Cardiovascular manifestations of hypereosinophilic syndromes. Immunol. Allergy Clin. North Am. 27, 457\u2013475 (2007).","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"85852_CR4","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.healun.2014.02.023","volume":"33","author":"M Groh","year":"2014","unstructured":"Groh, M. et al. Heart transplantation in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). J. Heart. Lung .Transplant. 33, 842\u2013850 (2014).","journal-title":"J. Heart. Lung .Transplant."},{"key":"85852_CR5","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.jaip.2019.12.011","volume":"8","author":"G Lef\u00e8vre","year":"2020","unstructured":"Lef\u00e8vre, G. et al. Idiopathic eosinophilic vasculitis: another side of hypereosinophilic syndrome? a comprehensive analysis of 117 cases in asthma-free patients. J. Allergy Clin. Immunol. Pract. 8, 1329\u20131340 (2020).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"85852_CR6","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.autrev.2019.06.004","volume":"18","author":"J Rohmer","year":"2019","unstructured":"Rohmer, J. et al. Distal ischemia as the initial presentation of hypereosinophilic syndrome-related arterial involvement: a case study and literature review. Autoimmun. Rev. 18, 828\u2013830 (2019).","journal-title":"Autoimmun. Rev."},{"key":"85852_CR7","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","volume":"124","author":"PU Ogbogu","year":"2009","unstructured":"Ogbogu, P. U. et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J. Allergy Clin. Immunol. 124, 1319\u20131325 (2009).","journal-title":"J. Allergy Clin. Immunol."},{"key":"85852_CR8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"SV Konstantinides","year":"2020","unstructured":"Konstantinides, S. V. et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur. Heart J. 41, 543\u2013603 (2020).","journal-title":"Eur. Heart J."},{"key":"85852_CR9","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1002\/art.1780330806","volume":"33","author":"AT Masi","year":"1990","unstructured":"Masi, A. T. et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis. Rheum. 33, 1094\u20131100 (1990).","journal-title":"Arthritis. Rheum."},{"key":"85852_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3109\/s10165-011-0571-z","volume":"22","author":"H Umehara","year":"2012","unstructured":"Umehara, H. et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod. Rheumatol. 22, 21\u201330 (2012).","journal-title":"Mod. Rheumatol."},{"key":"85852_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000075040","volume":"208","author":"P Joly","year":"2004","unstructured":"Joly, P. et al. Clinical criteria for the diagnosis of bullous pemphigoid: a reevaluation according to immunoblot analysis of patient sera. Dermatol. 208, 16\u201320 (2004).","journal-title":"Dermatol."},{"key":"85852_CR12","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nrrheum.2014.98","volume":"10","author":"P Khoury","year":"2014","unstructured":"Khoury, P., Grayson, P. C. & Klion, A. D. Eosinophils in vasculitis: characteristics and roles in pathogenesis. Nat. Rev. Rheumatol. 10, 474\u2013483 (2014).","journal-title":"Nat. Rev. Rheumatol."},{"key":"85852_CR13","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1001\/archderm.142.12.1606","volume":"142","author":"B Terrier","year":"2006","unstructured":"Terrier, B. et al. Superficial venous thrombophlebitis as the initial manifestation of hypereosinophilic syndrome: study of the first 3 cases. Arch. Dermatol. 142, 1606\u20131610 (2006).","journal-title":"Arch. Dermatol."},{"key":"85852_CR14","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1084\/jem.20161070","volume":"214","author":"S Uderhardt","year":"2017","unstructured":"Uderhardt, S. et al. Enzymatic lipid oxidation by eosinophils propagates coagulation, hemostasis, and thrombotic disease. J. Exp. Med. 214, 2121\u20132138 (2017).","journal-title":"J. Exp. Med."},{"key":"85852_CR15","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1182\/blood-2006-02-004945","volume":"109","author":"C Moosbauer","year":"2007","unstructured":"Moosbauer, C. et al. Eosinophils are a major intravascular location for tissue factor storage and exposure. Blood 109, 995\u20131002 (2007).","journal-title":"Blood"},{"key":"85852_CR16","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1093\/eurheartj\/ehv419","volume":"37","author":"J Riegger","year":"2016","unstructured":"Riegger, J. et al. Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium. Eur. Heart J. 37, 1538\u20131549 (2016).","journal-title":"Eur. Heart J."},{"key":"85852_CR17","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1084\/jem.172.4.1271","volume":"172","author":"MS Rohrbach","year":"1990","unstructured":"Rohrbach, M. S., Wheatley, C. L., Slifman, N. R. & Gleich, G. J. Activation of platelets by eosinophil granule proteins. J. Exp. Med. 172, 1271\u20131274 (1990).","journal-title":"J. Exp. Med."},{"key":"85852_CR18","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1007\/BF02536531","volume":"26","author":"A Ojima-Uchiyama","year":"1991","unstructured":"Ojima-Uchiyama, A. et al. Production of platelet-activating factor by human normodense and hypodense eosinophils. Lipids 26, 1200\u20131203 (1991).","journal-title":"Lipids"},{"key":"85852_CR19","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1182\/blood-2012-05-432088","volume":"121","author":"S Ueki","year":"2013","unstructured":"Ueki, S. et al. Eosinophil extracellular DNA trap cell death mediates lytic release of free secretion-competent eosinophil granules in humans. Blood 121, 2074\u20132083 (2013).","journal-title":"Blood"},{"key":"85852_CR20","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1182\/blood.2019000518","volume":"134","author":"C Marx","year":"2019","unstructured":"Marx, C. et al. Eosinophil-platelet interactions promote atherosclerosis and stabilize thrombosis with eosinophil extracellular traps. Blood 134, 1859\u20131872 (2019).","journal-title":"Blood"},{"key":"85852_CR21","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/j.1365-2141.1995.tb05211.x","volume":"90","author":"HY Mukai","year":"1995","unstructured":"Mukai, H. Y., Ninomiya, H., Ohtani, K., Nagasawa, T. & Abe, T. Major basic protein binding to thrombomodulin potentially contributes to the thrombosis in patients with eosinophilia. Br. J. Haematol. 90, 892\u2013899 (1995).","journal-title":"Br. J. Haematol."},{"key":"85852_CR22","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1172\/JCI116382","volume":"91","author":"A Slungaard","year":"1993","unstructured":"Slungaard, A., Vercellotti, G. M., Tran, T., Gleich, G. J. & Key, N. S. Eosinophil cationic granule proteins impair thrombomodulin function: A potential mechanism for thromboembolism in hypereosinophilic heart disease. J. Clin. Invest. 91, 1721\u20131730 (1993).","journal-title":"J. Clin. Invest."},{"key":"85852_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25945","author":"J Rohmer","year":"2020","unstructured":"Rohmer, J. et al. Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: data from 151 patients. Am. J. Hematol. https:\/\/doi.org\/10.1002\/ajh.25945 (2020).","journal-title":"Am. J. Hematol."},{"key":"85852_CR24","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.3389\/fimmu.2020.01765","volume":"11","author":"C Carpentier","year":"2020","unstructured":"Carpentier, C. et al. Eosinophilia Associated With CD3-CD4+ T Cells: Characterization and Outcome of a Single-Center Cohort of 26 Patients. Front. Immunol. 11, 1765 (2020).","journal-title":"Front. Immunol."},{"key":"85852_CR25","doi-asserted-by":"publisher","first-page":"8359","DOI":"10.1038\/s41598-020-65128-4","volume":"10","author":"Y Liu","year":"2020","unstructured":"Liu, Y., Meng, X., Feng, J., Zhou, X. & Zhu, H. Hypereosinophilia with concurrent venous thromboembolism: clinical features, potential risk factors, and short-term outcomes in a Chinese cohort. Sci. Rep. 10, 8359 (2020).","journal-title":"Sci. Rep."},{"key":"85852_CR26","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1177\/1076029609348647","volume":"16","author":"PRJ Ames","year":"2010","unstructured":"Ames, P. R. J., Margaglione, M., Mackie, S. & Alves, J. D. Eosinophilia and thrombophilia in churg strauss syndrome: a clinical and pathogenetic overview. Clin. Appl. Thromb. Hemost. 16, 628\u2013636 (2010).","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"85852_CR27","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/art.37721","volume":"65","author":"C Comarmond","year":"2013","unstructured":"Comarmond, C. et al. Eosinophilic granulomatosis with polyangiitis (churg-strauss syndrome) - clinical characteristics and long-term follow-up of the 383 patients enrolled in the FVSG cohort. Arthritis Rheum. 65, 270\u2013281 (2013).","journal-title":"Arthritis Rheum."},{"key":"85852_CR28","doi-asserted-by":"publisher","first-page":"670","DOI":"10.2174\/157016112801784594","volume":"10","author":"A Maino","year":"2012","unstructured":"Maino, A., Rossio, R., Cugno, M., Marzano, A. V. & Tedeschi, A. Hypereosinophilic syndrome, Churg-Strauss syndrome and parasitic diseases: possible links between eosinophilia and thrombosis. Curr. Vasc. Pharmacol. 10, 670\u2013675 (2012).","journal-title":"Curr. Vasc. Pharmacol."},{"key":"85852_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jaci.2010.04.011","volume":"126","author":"F Roufosse","year":"2010","unstructured":"Roufosse, F. & Weller, P. F. Practical approach to the patient with hypereosinophilia. J. Allergy Clin. Immunol. 126, 39\u201344 (2010).","journal-title":"J. Allergy Clin. Immunol."},{"key":"85852_CR30","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","volume":"132","author":"V Pengo","year":"2018","unstructured":"Pengo, V. et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 132, 1365\u20131371 (2018).","journal-title":"Blood"},{"key":"85852_CR31","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ejim.2015.04.022","volume":"26","author":"M Groh","year":"2015","unstructured":"Groh, M. et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur. J. Intern Med. 26, 545\u2013553 (2015).","journal-title":"Eur. J. Intern Med."},{"key":"85852_CR32","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/bmj.j1065","volume":"356","author":"MA Rodger","year":"2017","unstructured":"Rodger, M. A. et al. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. BMJ 356, 1065 (2017).","journal-title":"BMJ"},{"key":"85852_CR33","doi-asserted-by":"publisher","first-page":"e406","DOI":"10.1016\/j.amjmed.2020.03.040","volume":"133","author":"L Raj","year":"2020","unstructured":"Raj, L. et al. Evaluation of Venous Thromboembolism Recurrence Scores in an Unprovoked Pulmonary Embolism Population: A Post-hoc Analysis of the PADIS-PE trial. Am. J. Med. 133, e406\u2013e421 (2020).","journal-title":"Am. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85852-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85852-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85852-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T05:42:04Z","timestamp":1670046124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85852-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,18]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["85852"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-85852-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,18]]},"assertion":[{"value":"30 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GL: consulting fees from GlaxoSmithKline and AstraZeneca; JEK: consulting fees from GlaxoSmithKline and AstraZeneca; MG: consulting fees from GlaxoSmithKline and AstraZeneca. Other authors have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6388"}}